Marshall Wace, LLP An2 Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 96,111 shares of ANTX stock, worth $99,955. This represents 0.0% of its overall portfolio holdings.
Number of Shares
96,111
Previous 82,498
16.5%
Holding current value
$99,955
Previous $268,000
23.13%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ANTX
# of Institutions
48Shares Held
19.4MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA5.55MShares$5.77 Million0.18% of portfolio
-
Octagon Capital Advisors LP New York, NY3.22MShares$3.35 Million1.6% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.09MShares$2.17 Million0.26% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.62 Million0.5% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.55MShares$1.62 Million0.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $20.2M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...